Literature DB >> 10339486

von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.

R M van der Plas1, M E Schiphorst, E G Huizinga, R J Hené, L F Verdonck, J J Sixma, R Fijnheer.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) after bone marrow transplantation (BMT) differs from classic TTP in its clinical course and therapy. A characteristic of classic TTP is the inhibition of a plasma protease that specifically cleaves von Willebrand factor (vWF), thus reducing its multimeric size. We investigated whether this protease was also inhibited in BMT-associated TTP. Plasma from patients with classic or BMT-associated TTP was incubated with recombinant vWF R834Q, a vWF mutant with enhanced sensitivity to the protease. The proteolysis of vWF multimers was analyzed and quantified on Western blot. Metalloprotease activity was strongly inhibited in the classic TTP patient group. However, metalloprotease activity was normal in the BMT-associated TTP patient group. The difference in activity between the two patient groups was highly significant (P =.0016). The results indicate that the etiologies of classic and BMT-associated TTP are indeed different and provide an explanation for the lack of success of plasma exchange in BMT-associated TTP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10339486

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  S L Allford; S J Machin
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

Review 2.  Acute kidney injury in hematopoietic cell transplantation.

Authors:  Amy Kogon; Sangeeta Hingorani
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

Review 3.  Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2008-07       Impact factor: 3.443

4.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

Review 5.  Thrombotic microangiopathies: multimers, metalloprotease, and beyond.

Authors:  Joel Moake
Journal:  Clin Transl Sci       Date:  2009-10       Impact factor: 4.689

Review 6.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

7.  Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus.

Authors:  C J Frijns; R H Derksen; P G De Groot; A Algra; R Fijnheer
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

Review 8.  Thrombotic thrombocytopenic purpura: survival by "giving a dam".

Authors:  Joel L Moake
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

Review 9.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

10.  Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.

Authors:  Siribha Changsirikulchai; David Myerson; Katherine A Guthrie; George B McDonald; Charles E Alpers; Sangeeta R Hingorani
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.